Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Maximizing Pharmaceutical Licensing Opportunities | Jun 2011 | £2,425 | 100% |
| Technology Transfer Strategies A Guide to Maximizing Returns within The Pharmaceutical and Biopharmaceutical Industries |
May 2011 | £2,215 | 95% |
| Licensing Strategies of Large Pharmaceutical Companies Weak R&D Pipelines and The Patent Cliff Stimulate in-Licensing Activity |
Sep 2011 | £2,215 | 95% |
| Somaxon Pharmaceuticals Inc Premium Company Profile |
Mar 2008 | £315 | 94% |
| ZymoGenetics, Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 94% |
| Geron Corporation - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 94% |
| Endo Pharmaceuticals Holdings Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 94% |
| Angiotech Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 94% |
| Strategies for Innovation in Pharmaceutical R&D Enhancing R&D Through Biotech Alliances and CRO Outsourcing |
Mar 2005 | £475 | 94% |
| Genentech, Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 93% |
| Pharmaceutical Licensing Overview | Mar 2010 | £9,615 | 93% |
| Biogen Idec Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 93% |
| Sanofi-Aventis - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 93% |
| Effective Licensing & Commercialisation of Drug Delivery Systems 2006 |
Jul 2006 | £2,500 | 93% |
| Biotech M&A and Licensing Strategies Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines |
Apr 2011 | £2,215 | 92% |
| Maxygen, Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 92% |
| Bayer AG - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 92% |
| Mergers, acquisitions and licensing to continue drive industry growth | Oct 2006 | £1,070 | 92% |
| Helix BioMedix, Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 92% |
| Amgen Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 92% |
| Curis, Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 92% |
| Salix Pharmaceuticals, Ltd. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 92% |
| Baxter International Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 92% |
| Pharmaceutical Partnership Deal Terminations | Sep 2011 | £2,215 | 91% |
| Smith & Nephew Plc - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 91% |
| Innovative R&D Strategies and Models Outsourcing, Strategic Partnerships and Licensing to Improve Productivity and Contain Costs |
Sep 2011 | £2,215 | 91% |
| Trends in Pharmaceutical Portfolio Management Strategies to Maintain Profitability despite Adversity |
Sep 2008 | £2,405 | 91% |
| Flamel Technologies S.A. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 91% |
| Oral Drug Delivery Market Controlled and Sustained Release to be Major Revenue Generators |
Nov 2010 | £2,215 | 91% |
| Cephalon, Inc. – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 91% |
